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Abstract
The polarization of CD4+ T cells into distinct T helper cell lineages is essential for protective
immunity against infection, but aberrant T cell polarization can cause autoimmunity. The
transcription factor T-bet (TBX21) specifies the Th1 lineage and represses alternative T cell
fates. Genome-wide association studies have identified single nucleotide polymorphisms
(SNPs) that may be causative for autoimmune diseases. The majority of these polymor-
phisms are located within non-coding distal regulatory elements. It is considered that these
genetic variants contribute to disease by altering the binding of regulatory proteins and thus
gene expression, but whether these variants alter the binding of lineage-specifying tran-
scription factors has not been determined. Here, we show that SNPs associated with the
mucosal inflammatory diseases Crohn’s disease, ulcerative colitis (UC) and celiac disease,
but not rheumatoid arthritis or psoriasis, are enriched at T-bet binding sites. Furthermore,
we identify disease-associated variants that alter T-bet binding in vitro and in vivo. ChIP-seq
for T-bet in individuals heterozygous for the celiac disease-associated SNPs rs1465321 and
rs2058622 and the IBD-associated SNPs rs1551398 and rs1551399, reveals decreased
binding to the minor disease-associated alleles. Furthermore, we show that rs1465321 is an
expression quantitative trait locus (eQTL) for the neighboring gene IL18RAP, with
decreased T-bet binding associated with decreased expression of this gene. These results
suggest that genetic polymorphisms may predispose individuals to mucosal autoimmune
disease through alterations in T-bet binding. Other disease-associated variants may simi-
larly act by modulating the binding of lineage-specifying transcription factors in a tissue-
selective and disease-specific manner.
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Author summary
Research to date has identified many genetic variants that are more common in people
with a particular disease. However, in conditions that reflect multiple genetic and environ-
mental factors, it is difficult to know with certainty if and why any particular genetic vari-
ant is causative and the mechanism that may underlie this. Such variants are often outside
of protein-coding exons, instead falling in regions that regulate gene expression. In these
cases, the genetic variation may alter transcription factor binding and subsequent gene
expression. In this study, we have examined how genetic variation affects T-bet binding to
DNA, as a key transcriptional regulatory mechanism in the immune response. An inabil-
ity to mount this response effectively can result in increased susceptibility to infections or
cancer, while a response that is too strong, or wrongly targeted, can result in uncon-
trolled/chronic inflammatory and autoimmune conditions. We have found that T-bet
binding sites are specifically enriched in genetic variants associated with the mucosal auto-
inflammatory diseases UC, Crohn’s disease and celiac disease. We also identify genetic
variants that alter T-bet binding and gene expression. This discovery thus identifies a
molecular mechanism through which genetic variants can be associated with increased
risk of mucosal autoimmune disease.
Introduction
The differentiation of naïve CD4+ T cells into distinct T helper cell (Th) lineages is essential
for adaptive immunity. The original paradigm of interferon-gamma (IFN-γ) producing T-
helper 1 (Th1), and type-2 (Interleukin 4, 5, and 13) cytokine producing Th2 cells has
expanded to include both Interleukin-17 (IL-17) producing Th17 and anti-inflammatory T-
regulatory (Treg) cells. Th cell differentiation is controlled by a set of master regulatory or line-
age-specifying transcription factors, with the T-box family member T-bet necessary and suffi-
cient for Th1 cell differentiation. GATA3, RORγT and FOXP3 perform parallel roles in Th2,
Th17 and Treg cells, respectively [1]. Importantly, T-bet inhibits alternative lineage fate speci-
fication, repressing both the Th17 and Th2 lineages [2–4].
Inappropriate Th cell activation and polarization can lead to autoimmunity. Worldwide,
autoimmune and auto-inflammatory diseases are now estimated to affect nearly 10% of the
population [5]. The incidence of inflammatory bowel diseases (IBD), including Crohn’s dis-
ease and UC, and celiac disease, is rising rapidly, with more than 1.4 million people affected in
the USA alone [6]. A role for T-bet is particularly apparent in the mucosal immune system and
has been linked to IBD and celiac disease [7]. The expression of T-bet is upregulated in lamina
propria T cells of patients with Crohn’s and celiac disease and ex vivo culture of biopsies from
untreated celiac patients with gliadin increases T-bet expression through STAT1 activation
[8,9]. In addition to this, it is now apparent that mucosal inflammation is also driven by IL-17,
which is enhanced by IL-23 receptor signals in effector T cells [10]. Loss of T-bet in the innate
immune system leads to a transmissible form of ulcerative colitis in the TRUC (T-bet and Rag
deficient Ulcerative Colitis) model, driven by transcriptional derepression of TNF in colonic
mononuclear phagocytes [11–13]. This susceptibility has also been shown to be dependent on
IL-17 and mediated via repression of IL-7 receptor expression by T-bet in innate lymphoid
cells (ILCs) [11]. T-bet has subsequently been shown to play a role in the development of the
NKp46+ CCR6- subset of IL-22 expressing ILCs that, in turn, are important for protecting the
epithelial barrier during Salmonella enterica infection [14,15].
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Autoimmune diseases cluster in families, suggesting a large genetic component [16].
Genome-wide association studies (GWAS) have identified hundreds of risk loci for autoim-
mune diseases, including for IBD and celiac disease [16–23]. The majority of autoimmune dis-
ease-associated SNPs lie outside of gene coding regions in intergenic or intronic regions [24].
This can make it challenging to understand the molecular basis of how a genetic variant pre-
disposes to disease. Furthermore, the causal variant can be difficult to identify from the large
clusters of SNPs in linkage disequilibrium that tend to be identified by GWAS. Thus, efforts
have been made to identify SNPs located within regulatory elements marked by open chroma-
tin, histone modifications associated with active enhancers or known/predicted transcription
factor binding sites [21,24–32]. Some of these variants have been shown to modulate transcrip-
tion factor binding or epigenetic regulation. Genetic variants that alter DNase I hypersensitiv-
ity [27,33,34], DNA methylation [35–38], histone modification [27,39–43], and the binding of
transcriptional regulators to DNA [27,33,34,44–51], have been identified, suggesting potential
causal mechanisms.
Although previous studies have demonstrated enrichment of transcription factor binding
sites at disease-associated polymorphisms, whether specific disease causing variants act to alter
the binding of T cell lineage-specifying factors has not been investigated. Having previously
mapped T-bet binding across the genome in human Th1 cells [52–54] we used a systematic
functional GWAS (fGWAS) approach to determine the degree to which disease-associated
SNPs were enriched within T-bet binding sites. SNPs were then tested for effects on T-bet
binding in vitro using a novel flow cytometric assay and in vivo by allele-specific ChIP-seq. We
report here that SNPs associated with mucosal inflammatory diseases are selectively enriched
at T-bet binding sites. Furthermore, we show that the celiac disease associated variants of
rs1465321 and rs2058622, and the IBD-associated variants of rs1551398 and rs1551399, exhibit
decreased T-bet binding in vivo. We further demonstrate that the genes associated with these
SNPs, IL18RAP and TRIB1, respectively, are transcriptionally regulated by T-bet and that
rs1465321 is an expression quantitative trait locus (eQTL) for IL18RAP. Taken together, these
data mechanistically link alterations in T-bet binding to disease predisposition.
Results
Disease-associated SNPs at T-bet binding sites
To identify disease-associated polymorphisms at T-bet binding sites, we compared the locations
of GWAS hits listed in the National Human Genome Research Institute (NHGRI) catalogue
[55] with binding sites for T-bet in primary human Th1 cells [52–54]. As the published trait-
associated SNP may not be the most functionally relevant [28], SNPs in high linkage disequilib-
rium LD (r2 >0.8) were also examined. This returned a list of 926 unique SNPs located at T-bet
binding sites (hereafter referred to as T-bet hit-SNPs; Fig 1A and 1B, S1A Fig and S1 Table). In
line with previous reports, a minority (143) of the T-bet hit-SNPs were the putative causal SNP
from GWAS data, with the others being in high LD (total of 621 independent LD blocks).
Examination of the location of T-bet hit-SNPs in relation to protein-coding genes revealed that
the majority (63%) were distal (>1 kb) to gene promoters. As expected, H3K27ac and DNaseI
hypersensitivity were highly enriched in Th1 cells at T-bet hit-SNPs compared with all disease-
associated SNPs, consistent with these being located within active regulatory elements (Fig 1C).
SNPs associated with mucosal immune diseases are enriched at T-bet
binding sites
As T-bet is only expressed in cells of the immune system, we hypothesised that T-bet hit-SNPs
would be primarily associated with autoimmune diseases. To test this, we used fGWAS [56], a
Disease-associated genetic variation alters T-bet binding
PLOS Genetics | DOI:10.1371/journal.pgen.1006587 February 10, 2017 3 / 23
hierarchical model that assesses relative enrichment of GWAS associations within various
functional elements. This model splits the genome into large blocks (larger than regions of
linkage disequilibrium), assesses whether each block contains a SNP associated with the trait
of interest or not and then searches among supplied functional annotations for those that
improve the likelihood of predicting the presence of a trait-associated SNP, finally predicting
which SNP in the block is most likely causal.
To test whether disease-associated SNPs were enriched at T-bet binding sites, we gathered
GWAS data for the Th1-associated auto-inflammatory conditions celiac disease, Crohn’s dis-
ease, UC, rheumatoid arthritis (RA), psoriasis and, as a negative non-immune control, coro-
nary artery disease (Fig 2). We compared T-bet binding sites with a number of other relevant
functional annotations, including Th1 and Th2 cell DHS [57], H3K27ac [58], and sites of his-
tone modification and transcription factor binding in immune cell lines from the ENCODE
project [26] and other sources (S2 Table). Notably, we found that SNPs associated with all of
the mucosal immune-mediated diseases tested (Crohn’s disease, UC and celiac disease) were
enriched at T-bet binding sites, with the effect in Crohn’s disease being particularly striking.
Enrichment at T-bet binding sites was similar to, or stronger than, DHS and H3K27ac and, in
Fig 1. T-bet binding at polymorphic sites. A. Heat map showing T-bet occupancy around SNPs located within T-bet binding sites (T-bet hit-
SNPs). Each row is centred on a single SNP, with T-bet binding shown across the genomic region stretching 2 kb up and downstream.
Sequence reads (per million total reads) at each position are represented by colour, according to the scale on the left. Negative IgG ChIP-seq
data are shown on the right at the same loci. B. T-bet binding at two example T-bet hit-SNPs. The number of sequencing reads from T-bet, IgG
control and H3K27ac ChIP-enriched DNA are plotted per million input-subtracted total reads and aligned with the human genome. DNaseI
hypersensitivity data (2 replicates) are from ENCODE. C. Left: Average number of ChIP-seq reads for H3K27ac and control total H3 in human
Th1 cells plotted against the genomic distance from T-bet hit-SNPs or the complete set of GWAS SNPs plus those in high LD. Right: Average
number of sequencing reads measuring DNaseI hypersensitivity plotted against genomic distance.
doi:10.1371/journal.pgen.1006587.g001
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Fig 2. SNPs associated with mucosal autoimmune diseases are enriched at T-bet binding sites.
Scatter plots showing log-odds ratio against –log(10) p-value for the enrichment of disease-associated SNPs
at different functional annotation datasets (DHS, histone modification, FAIRE-seq and transcription factor
binding). Selected enriched functional annotation datasets are highlighted. GM12878 H3K4me1 indicates
sites of H3K4me1 in the GM12878 lymphoblastoid cell line. Celiac disease, Crohn’s disease and UC-
associated SNPs, but not RA, psoriasis or coronary artery disease-associated SNPs, are strongly enriched at
T-bet binding sites (red dots with arrows).
doi:10.1371/journal.pgen.1006587.g002
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the case of Crohn’s and celiac disease, stronger than any other sets of transcription factor bind-
ing sites. As expected, SNPs associated with coronary artery disease were not enriched at T-bet
binding sites. Of interest, no enrichment for T-bet binding sites was observed for RA- or psori-
asis-associated SNPs, suggesting a specific role for altered T-bet binding in mucosal inflamma-
tory disease.
To confirm that T-bet binding is enriched at IBD-associated SNPs, we compared T-bet
binding sites to a set of credible SNPs identified at 94 IBD-associated loci [21]. We found that
T-bet binding sites were more highly associated with credible SNPs than other SNPs at the
same loci (93 bound by T-bet, p = 1.4x10-5, Fisher exact test). Furthermore, within the set of
credible SNPs, the higher the posterior probability for causality, the more likely that the SNP
overlapped a T-bet binding site (p = 6.3x10-6, continuous binomial regression, S1B Fig). The
association of T-bet binding with causal SNPs is highlighted by the finding that, of the 93 cred-
ible SNPs bound by T-bet, 11 are the lead variants for their loci. Three of these (rs74465132,
rs1887428 and rs61839660) have a posterior probability for causality of greater than 95%.
These data suggest that the strong association of these SNPs with IBD is related to T-bet bind-
ing at these sites.
Detection of altered T-bet binding at disease-associated variants by
OligoFlow
Having identified a set of SNPs overlapping T-bet binding sites, we next asked whether these
sequence variants altered T-bet binding. The traditional pull-down technique is time intensive
and semi-quantitative. Therefore, we explored whether transcription factor binding could be
assayed using a flow cytometric readout. In this technique, which we call OligoFlow, a fluoro-
chrome-labelled antibody for the transcription factor of interest is added to the oligonucleo-
tide-bead / lysate mix, and the Median Fluorescence Intensity (MFI) of the beads is assessed by
flow cytometry as a quantitative measure of binding efficiency (Fig 3A).
To validate this new technique, a positive control oligonucleotide (Motif+) was designed to
incorporate the previously identified consensus sequence [54] surrounded by non-specific
sequence (S3 Table). A negative control oligo (Motif-) incorporated mutations of two key resi-
dues within the motif. OligoFlow was conducted with lysate from either the YT human cell
line, which constitutively expresses T-bet [59], or lysate from primary human CD4+ cells
polarised under Th1 conditions in culture. The positive and negative control oligonucleotides
showed a clear difference in MFI (Fig 3A) and thus OligoFlow can successfully discriminate
positive and negative transcription factor binding events.
We then proceeded to test a subset of our T-bet hit-SNPs that were also associated with
H3K27ac or near genes of immunological interest. SNPs that showed differential binding were
tested at least five times. Within each experiment, the MFI of each allele was normalised to the
MFI of the negative control and significantly altered binding between alleles across all experi-
ments was assessed using a paired t-test. Three T-bet hit-SNPs exhibited significantly different
binding to the two alleles; rs1465321, located within the second intron of IL18R1, rs1006353,
22.5 kb upstream of MTIF3, and rs11135484, within an intron of ERAP2 (Fig 3B). Differential
T-bet binding to the two alleles of rs1465321 were confirmed by traditional oligonucleotide
pull-down (S2 Fig). All 3 SNPs are [A/G] with A as the minor allele. In each case, allele A is
also in LD with alleles associated with for the trait under investigation. rs1465321 is in high LD
with multiple SNPs associated with celiac disease, including rs13015714 and rs917997, identi-
fied as the strongest risk alleles for celiac disease in 2q12.1 [18,60], with the disease-associated
alleles linked to reduced IL18RAP expression [60]. rs1465321 and rs11135484 have also been
associated with Crohn’s disease [18,22,60,61], but not in a more recent study [21]. For
Disease-associated genetic variation alters T-bet binding
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Fig 3. Genetic variants alter T-bet binding in vitro. A. Outline of the OligoFlow method. Double-stranded
oligonucleotides are annealed to beads and incubated with cell lysate containing the transcription factor of
interest. Fluorescently labelled antibody is added and MFI of the beads measured by flow cytometry. The
Disease-associated genetic variation alters T-bet binding
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rs1465321 and rs1006353, the minor disease-associated A allele binds T-bet less strongly than
the G allele (Fig 3C–3F). In contrast, for rs11135484, the A allele binds T-bet more strongly
than the G allele (Fig 3G and 3H). We conclude that disease-associated genetic variants can
alter T-bet binding to DNA in vitro.
SNPs affecting T-bet binding cannot reliably be identified by motif
analysis
Motif analysis has often been used to predict transcription factor binding sites affected by
genetic variants. We previously derived a consensus T-bet motif from T-bet binding sites in
human Th1 cells [54] and repeated this analysis with duplicate T-bet ChIP-seq data (Fig 4).
The three T-bet hit-SNPs that showed altered binding in OligoFlow were then examined for
whether they disrupted such a T-bet binding motif. In the case of rs1006353, the G allele
formed part of a T-bet binding motif, whereas the A allele abolished this binding site (Fig 4B).
However, neither of the other two SNPs, rs1465321 and rs11135484, overlapped a predicted T-
bet binding motif (Fig 4B). Thus, over-reliance on motif analysis can result in SNPs with the
potential to alter transcription factor binding sites being missed and highlights the importance
of using experimental validation to confirm binding of the relevant transcription factor.
Differential T-bet binding at disease variants in vivo
We next sought to confirm that T-bet exhibited differential binding to disease-associated
SNPs in vivo. We focused on rs1465321, because it lies within the IL18R1/IL18RAP gene
locus that we have previously identified as a T-bet target [54] and because disease-associated
alleles in high LD are associated with reduced IL18RAP expression and disease [60]. Primary
naive CD4+ T cells were purified from the peripheral blood of two individuals heterozygous
for this SNP and were polarised into the Th1 lineage. We then performed ChIP-seq for T-bet
in these cells, as previously described [54]. We aligned the reads for the T-bet ChIP-enriched
DNA and input controls to the reference human genome and then counted the number of
reads matching the major or minor alleles in the inputs and ChIP samples. In the input DNA
samples, there were approximately equal numbers of reads for the two alleles in both individ-
uals. In comparison, the T-bet ChIP reads showed significantly lower enrichment for the
minor A allele in both donors (Fig 5A and 5B). There was also a significant allelic imbalance
for T-bet binding at the neighbouring SNP rs2058622, which is in high LD (r2 = 1.0) with
rs1465321 (Fig 5A and 5B). To determine whether T-bet exhibited allelic imbalanced binding
at any other loci, we identified all SNPs that exhibited heterozygosity in both individuals. Of
the heterozygous SNPs that overlapped a T-bet binding site, 19 exhibited significant allelic
imbalanced binding in both donors after adjustment for multiple hypothesis testing
histograms show the MFI of beads coated with oligonucleotides containing a T-bet binding motif (Motif +) or a
mutated sequence (Motif -) after incubation with YT lysate, normalised for the number of beads acquired. B.
Summary of OligoFlow results for the 11 SNPs tested. In each case, MFI for both alleles is normalised such
that the negative control equals 1. Normalised MFI for the lowest binding allele was then subtracted from the
value for the highest binding allele. Each cross represents one experiment, with the average difference
between alleles represented by a horizontal line. * Significantly different binding between the two alleles
(p < 0.05, paired t-test.) C. Representative experiment measuring the binding of T-bet to the A and G alleles of
rs1465321. Data for the different oligonucleotide probes are separated according to the key on the right and
the MFI is also shown. D. Bar chart showing all replicate experiments for rs1465321. The y-axis shows MFI for
each allele normalised to the MFI of the negative control oligonucleotide (set to 1). Each pair of bars
represents one experiment, performed with either YT cells (YT) or Th1-polarised primary CD4+ cells (Th1). E.
As C but for rs1006353. F. As D but for rs1006353. G. As C but for rs11135484. H. As D but for rs11135484.
doi:10.1371/journal.pgen.1006587.g003
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(Fig 5C, S4 Table). These included the IBD-associated SNPs rs1551398 and rs1551399 [21],
situated 86bp apart and downstream of TRIB1 (Fig 5C, S1 and S3 Figs). We conclude that the
two alleles of rs1465321 exhibit different levels of T-bet binding in vivo, with the disease asso-
ciated A allele bound significantly less, and that the credible IBD variants rs1551398 and
rs1551399 also influence T-bet binding.
Regulation of Il18rap and Trib1 expression in T-bet-/- Th1 cells
Having identified rs1465321, rs2058622, rs1551398 and rs1551399 as disease associated SNPs
that modulate T-bet binding in vivo, we next determined whether there was a functional rela-
tionship between T-bet binding and the genes associated with these SNPs. rs1465321 and
rs2058622 are in high LD with SNPs associated with low expression of IL18RAP in celiac dis-
ease [60]. The IBD-associated SNPs rs15513998 and rs1551399 are associated with TRIB1 [21].
To determine whether there was a functional relationship between T-bet binding and
IL18RAP and TRIB1 expression, we compared gene expression profiles of wild type and T-
bet-/- naïve CD4+ T cells polarised in Th1 conditions. As expected, genes known to be
Fig 4. Motif analysis does not reliably predict impact on T-bet binding. A. T-bet binding, IgG control and H3K27ac modification (ChIP-seq
reads/million) at the genomic regions surrounding the SNPs rs1465321 (left), rs11135484 (center) and rs1006353 (right). The location of the
SNPs are indicated by dashed vertical lines. The regions highlighted in grey are expanded in B. B. Expanded view of T-bet binding at the
regions highlighted in grey in A. The locations of sequences matching the identified T-bet DNA binding motif (inset) are marked by red lines,
together with their score (a negative value indicates a poor match). Only rs1006353 overlaps a T-bet DNA binding motif and the A allele is
predicted to disrupt the motif and T-bet binding.
doi:10.1371/journal.pgen.1006587.g004
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positively regulated by T-bet were significantly downregulated in T-bet-/- cells, including Inter-
feron-γ (Ifng) and Tim-3 (Havcr2), while the housekeeping genes Gapdh, Actb and Hprt
remained unchanged (Fig 6A). Il18rap was also significantly downregulated in the absence of
T-bet, implying a positive regulatory role for T-bet in modulating its expression (Fig 6A). In
contrast, Trib1 was significantly upregulated in T-bet-/- cells, implying that T-bet functions to
repress this gene. Consistent with a direct role for T-bet in regulating Il18rap and Trib1 expres-
sion, multiple T-bet binding sites were located within intronic regions of murine Il18rap and
downstream of Trib1 (S4 Fig). Thus, these data support a direct role for T-bet binding in the
regulation of IL18RAP and TRIB1 expression.
Fig 5. Genetic variants alter T-bet binding in vivo. A. Genomic context of rs1465321 and rs2058622, which is in high LD (r2 = 1.0) with
rs1465321. B. T-bet ChIP and input sequencing reads that cross rs2058622 (chr2: 102985274–102985565; left) or rs1465321 (chr2:
102986477–102986768; right) in two donors heterozygous for rs1465321. In each case, the number of reads that match the reference
allele are shown in black and the alternative allele in green. C. T-bet ChIP and input (Inp) sequencing reads at the set of 19 additional
heterozygous SNPs that exhibited allelic imbalanced T-bet binding. For each SNP, the color shows fold-enrichment in the number of
sequencing reads matching the Ref or Alt allele, relative to the average number of reads across all samples, as indicated by the scale on
the right hand side. SNPs are divided into those exhibiting greater T-bet binding to the reference (Ref) allele (Ref > Alt, top) or the
alternative (Alt) allele (Alt >Ref, bottom).
doi:10.1371/journal.pgen.1006587.g005
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Fig 6. rs1465321 is an eQTL for IL18RAP and celiac disease. A. RNA abundance (size factor-normalised counts) for
selected genes in wild type (WT) and T-bet deficient (T-bet KO) naive lymphocytes cultured under Th1 polarising conditions.
* significant change in expression (p<0.05, Wald test after Benjamini-Hochberg correction). B. “Locus-zoom” plot showing
the distribution of association p-values for celiac disease in the IL18RAP/IL18R1 chromosome region (genes shown below
Disease-associated genetic variation alters T-bet binding
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rs1465321 is associated with IL18RAP expression and co-localises with
celiac disease risk
We next explored whether the genotype of rs1465321 could control the expression of nearby
genes and how this potential eQTL related to celiac disease susceptibility (Fig 6B). Celiac dis-
ease association was based on a case control association study of 12,041 celiac disease cases
and 12,228 controls [23]. Using a gene expression dataset of 1,214 samples [62] we found a
strong correlation between rs1465321 genotypes and IL18RAP expression level (p<10−100, Fig
6C). No other gene showed a significant association with rs1465321. However, this SNP did
not display the greatest eQTL association compared with other variants in the region, which
could suggest a lack of a causal role. Moreover, using a previously developed methodology
[63], we established that the eQTL and disease association signals in the IL18RAP regions were
unlikely to be driven by the same genetic variant (posterior probability supporting a shared
variant < 1%, Fig 6C). However, a stepwise regression analysis of the eQTL data shows that
after accounting for the primary eQTL signal (conditional on rs1985329), a second eQTL asso-
ciation was clearly detectable (p<10−30). This suggested that at least two independent variants,
with distinct biological mechanisms, are controlling IL18RAPmRNA expression. Interestingly,
this secondary eQTL signal co-localized with the celiac disease risk signal (Fig 6D, posterior
probability supporting a shared variant > 99%). Moreover, rs1465321 is one of the most
strongly associated genetic variants for this secondary eQTL signal, with the disease-associated
A allele, which exhibited reduced T-bet binding, associated with reduced IL18RAP expression.
Therefore, our combined fine-mapping disease eQTL data are consistent with rs1465321
affecting IL18RAP expression through altered binding of T-bet.
Discussion
We have found that IBD and celiac disease-associated SNPs are significantly enriched at T-bet
binding sites. Surprisingly, this association is not observed for RA or psoriasis, suggesting it
may be specific for mucosal inflammatory disease. Furthermore, we have identified genetic
variants that alter T-bet binding to DNA, both in vitro and in vivo, including rs1465321, which
we also identify as an eQTL for IL18RAP and celiac disease. Thus, these data provide a mecha-
nistic explanation for why a single base change at this locus is associated with changes in gene
expression and disease risk.
Although some studies have identified sequence variants that modulate transcription factor
binding, alterations in the binding of Th lineage-specifying factors at disease-associated vari-
ants has not previously been identified. Our discovery that SNPs associated with IBD and
celiac disease alter T-bet occupancy reveals that genetic variants can have a significant impact
on the function of key master regulator transcription factors that govern cell fate. The strong
association of T-bet binding sites with mucosal autoimmune/inflammatory diseases suggests
that other disease-associated variants also act to alter the binding of this critical immune
panel D). The x-axis shows the chromosome position. Colors show the level of linkage disequilibrium with rs1465321, which
is indicated with a purple spot. C. “Locus-zoom” plot showing the distribution of association p-values for IL18RAP eQTL in
1,214 whole blood RNA samples. The Bayesian statistic for colocalisation with the celiac disease signal shows a posterior
probability against colocalisation (PP3) greater than 99%, indicating that this primary whole blood IL18RAP eQTL signal is
not compatible with a shared causal variant with celiac disease. D. “Locus-zoom” plot showing the secondary IL18RAP
eQTL (conditional on rs1985329) signal in the same 1,214 whole blood RNA samples. For this secondary signal, the
Bayesian statistic for colocalisation with the celiac disease signal shows a posterior probability in favour of colocalisation
(PP4) greater than 99%, indicating that this secondary whole blood IL18RAP eQTL signal is compatible with a shared causal
variant with celiac disease.
doi:10.1371/journal.pgen.1006587.g006
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regulator, with important consequences for T cell polarisation and lineage-specific gene
expression.
That T-bet binding sites are associated with mucosal autoimmune disease, but not with RA
or psoriasis is somewhat surprising, because all of these diseases have been linked to aberrant
Th1 responses [2]. However, mucosal disease is more strongly associated with aberrant Th17
responses, which are repressed by T-bet [3,4,64,65], providing a mechanistic rationale for our
findings. We and others have recently shown that T-bet plays a critical and non-redundant
role in the function of ILCs [2,7,11–15]. It is therefore feasible that the association of mucosal
autoimmune disease-associated SNPs with T-bet binding sites reflects alterations to T-bet
binding in ILCs, which have a key regulatory role at mucosal surfaces. Expanding our fGWAS
analysis to other autoimmune conditions will be necessary to fully establish the specificity of
the association of T-bet with SNPs associated with mucosal disease.
Significantly, we have demonstrated that T-bet binding is enriched at disease-associated
SNPs that have high posterior probabilities [21]. This suggests that more T-bet bound variants
will be discovered when other IBD loci are subjected to fine-mapping analysis. We further
found that the disease-associated alleles of rs1551398 and rs1551399 both reduce T-bet binding
in vivo. These SNPs are located upstream of TRIB1, a gene that is upregulated in the mucosa of
both UC and CD patients [66]. Consistent with this, we find that T-bet functions to repress
Trib1 expression, suggesting that the disease-associated alleles may increase disease risk by
abrogating T-bet-mediated repression of this gene. T-bet also binds at 2 other sites near TRIB1
(rs28510097 and rs1551400) and, together, these 4 SNPs account for 55% posterior probability
of association for this locus [21].
We also identified rs1465321, located within an intron of IL18R1, to exhibit allele-imbal-
anced T-bet binding. This SNP is an eQTL for IL18RAP and celiac disease risk, with the minor
disease-associated allele linked with reduced T-bet binding and IL18RAP gene expression.
IL18RAP and IL18R1 together form the IL-18 receptor. Signaling through this receptor, IL-18
synergizes with IL-12 to induce IFNγ. rs1465321 is in high LD with the lead SNP in this locus
for celiac disease [60]. Although our data are consistent with rs1465321 altering IL18RAP
expression through altered binding of T-bet, we cannot rule out that variants in strong LD
with rs1465321 could also be causal, such as rs2058622 that also exhibits allele-imbalanced T-
bet binding. Given that T-bet acts through multiple sites to regulate its target genes [52, 54, 67,
68], it is likely to be the combined effect of the haplotype that is relevant. ChIP-seq for T-bet in
individuals heterozygous for other disease-associated SNPs will likely reveal further examples
of genetic variants that modulate T-bet binding.
Our finding that there are two independent eQTLs for IL18RAP, and that only one of these
is associated with celiac disease (Fig 6), suggests that the level of IL18RAP expression may not
be functionally relevant for disease susceptibility. Alternatively, it is possible that the two inde-
pendent eQTLs for IL18RAP represent different enhancers that mediate transcriptional activa-
tion in different cells or in response to different stimuli, and that IL18RAP expression level is
only relevant for celiac disease in one cell type or in response to a particular signal.
Attempts to determine the likely effect of non-coding sequence variants have mostly
focused on identifying overlapping transcription factor binding motifs or overlapping sites of
transcription factor binding, DNase I hypersensitivity or DNA and histone modification. Our
analysis of allele-specific T-bet ChIP-seq data shows that genetic variants within transcription
factor binding sites do not necessarily alter transcription factor binding. Similarly, genetic vari-
ants that do impact transcription factor binding do not necessarily lie within the predicted
motif. Thus, confirmation of allele-specific binding events is necessary to confirm that a SNP
does indeed impact transcription factor function and provides a mechanistic link between
genetic variation and disease risk.
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We have established the feasibility of using flow cytometry to assay allelic effects on tran-
scription factor binding, and validated this technique through both the traditional pull-down
assay and allele-specific ChIP-seq. As flow cytometric methods can be easily automated, this
method provides a more rapid means to assay large numbers of allelic variants compared to tra-
ditional pull-down methods. Using this OligoFlow method, we identified alterations in T-bet
binding at rs11135484, in high LD with a SNP associated with Crohn’s disease and with
rs1006353, the closest neighbor of which is MTIF3, associated with body mass index [69]. Inter-
estingly, T-bet has been linked with regulation of insulin sensitivity and visceral adiposity [70].
In summary, we have identified a specific association between T-bet binding sites and
mucosal autoimmune disease variants and determined that such genetic variants modulate T-
bet binding in cells. This suggests that altered binding of T cell master regulators can predis-
pose individuals to specific autoimmune and inflammatory conditions. This study establishes
a scalable method that can be used to explore the impact of genetic variation on the function of
other lineage-specifying transcriptional factors. These insights will identify molecular mecha-
nisms that underlie the genetic basis of autoimmune diseases and suggest new therapies for
their treatment.
Materials and methods
T-bet hit-SNP identification
ChIP-seq for T-bet in human Th1 cells was performed previously [53–54] (GEO accessions:
GSE31320 and GSE62486) and binding sites were identified from the merged dataset with
MACS 1.4 (p<10−7) [71]. The positions of T-bet peaks were identified relative to gene tran-
scription start sites annotated in RefSeq. The GWAS catalogue was downloaded from the
NHGRI [55] on December 12th 2014. SNPs were checked against dbSNP and 4 SNPs called
‘suspect’ removed. SNPs that had been merged with other IDs were checked against HapMap3
and the ID given in HapMap3 used in downstream analysis. SNPs not in HapMap3 were
removed, giving 13,936 autosomal SNPs in the final analysis. Data were analysed using the bio-
conductor snpMatrix programme (recently updated to snpStats) [72, 73]. SNPs in high LD
(r2> 0.8 with a SNP from the GWAS catalogue) were obtained from HapMap3 [74], giving a
total of 127,594 SNPs. These were then overlapped with the T-bet binding sites. To identify the
number of independent LD blocks were represented by the 926 T-bet bound SNPs, we used
the SNPclip module of LDlink to reduce any SNPs in high LD to a single tag SNP, using a R2
threshold of 0.8 and a MAF (Minimum Allele Frequency) threshold of 0.01.
Comparison to H3K27ac and DHS
ChIP-seq data for IgG, H3K27ac and total H3 were taken from GSE62486. Sequence reads
were trimmed to remove low quality bases and to remove adapters and aligned using Bowtie
(default settings) to hg19. Peaks of H3K27ac were identified with MACS (p<10−7) [71]. DHS
data were obtained from ENCODE (GEO accession GSM736592) [75,76]. Average binding
profiles were calculated across 4 kb windows centred on hit-SNPs using ngsplot [77]. Data
were visualized on the UCSC genome browser by calculating tag density in 10bp windows,
normalizing to reads per million total reads and subtracting background (input for T-bet and
H3 for H3K27ac), as described [54].
Human SNP genotyping
Individuals heterozygous for rs1465321 were identified from the Twins UK cohort at the
Guy’s and St Thomas’ NHS Foundation Trust (GSTT) Bioresource, where HumanHap610Q
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Illumina array data is available for all registered participants. The Illlumina calling algorithm
[78] was used to assign genotypes from array data. Before imputation, quality controls were
applied, with exclusion of all samples with: (1) call rate<98%, (2) heterozygosity across all
SNPs2 standard deviations from the sample mean; (3) evidence of non-European ancestry
as assessed by PCA comparison with HapMap3 populations; (4) observed pairwise IBD proba-
bilities suggestive of sample identity errors. We also corrected zygosity based on IBD probabili-
ties. Quality controls were also applied to each individual SNP using the following exclusion
criteria: (1) Hardy-Weinberg p-value <10−6 (assessed in a set of unrelated samples); (2) MAF
<1% (assessed in a set of unrelated samples); (3) SNP call rate<97% (SNPs with MAF5%)
or< 99% (for 1%MAF < 5%). Finally all the alleles were aligned to the forward strand of
HapMap2. After completion of both sample and SNP quality controls checks, imputation was
performed using the IMPUTE software package (v2) [79] using HapMap2 as a reference panel
(HapMap2, rel. 22, combined CEU+YRI+ASN panels). Heterozygous SNPs were selected
using PLINK (version 1.0.7) [80] “—recode-rlist” option on the imputed dataset. A final QC
stage was applied on all the heterozygous SNPs, excluding all those polymorphisms with an
imputation quality score 0.8.
Allele-specific T-bet ChIP-seq
In accordance with the Department of Health’s Research Governance Framework for Health
and Social Care, ethical approval for this study was gained from the South London Research
Ethics Committee (Ref:15/LO/0151), and from the Department of Research and Development
at GSTT NHS Trust (Ref:RJ115/N122). Approval was also gained from the GSTT National
Institute of Health Research (NIHR) Bioresource for recruitment of individuals registered on
the Bioresource and heterozygous for rs1465321. All of the subjects in this study gave written
consent. Blood was taken from two individuals heterozygous for the desired SNP. CD4+ T
cells were purified from whole blood leukocytes using CD4 microbeads (Miltenyi Biotec) and
naïve CD4+ T-cells sorted by FACS selection for CD4+ CD45RA+ CD4RO- CD25- CCR7
+ cells. Sorted naïve T-cells were activated with anti-CD3/CD28 and polarized under Th1 con-
ditions (IL2, IL12 and anti-IL4) for 7 days [54]. Cells were then crosslinked and ChIP-seq for
T-bet performed with a custom-made polyclonal antibody [54]. Libraries were quantified
using the KAPA library quantification kit and sequenced (150 bp single-end) with an Illumina
NextSeq. Sequence reads were trimmed and aligned to hg19 as before. Peak regions for both
donor 1 and 2 were identified separately using MACS 1.4. Broad shallow peaks were filtered,
intersecting peaks identified with Bedtools (n = 8185), and then narrowed to the central 400
bp. Potential SNP variants within these intersecting peak regions were extracted from dbSNP
version 138 (assembly hg19, n = 490,310). SNP sites for further analysis were determined from
the Bowtie aligned bam files as containing >1 reads with both Ref and Alt bases in both ChIP
and Input samples from both donors (n = 9058). This list was then compared to the set of het-
erozygous SNPs identified by the SNP array analysis (n = 2621 high confidence heterozygous
SNPs). Reads surrounding these sites were extracted into R using the Bioconductor Rsamtools
and GenomicRanges packages. The reads were split by Ref and Alt alignment for visualization
using the GenomicAlignments package.
To test whether T-bet exhibited allelic imbalanced binding at rs1465321 and at SNPs in
high LD, we used a binomial test. Donor 1 and 2 p-values were combined using the Fisher
method. rs1465321 and rs2058622 showed significant allelic imbalance (p<0.01) in the T-bet
ChIP samples and allelic balance (p>0.1) in the Input samples. To identify other heterozygous
SNPs that exhibited allelic-imbalanced T-bet binding, we used a binomial test to identify het-
erozygous SNPs at which significantly more reads were reported for one allele compared to
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the other in both T-bet ChIP samples (Benjamini-Hochberg adjusted p<0.05) but not imbal-
anced in the Input samples from either donor (unadjusted p>0.4). This produced a list of 19
additional SNPs (S4 Table).
T-bet ChIP-seq data from donors 1 and 2 heterozygous for rs1465321 are available at GEO
under accession GSE81881.
RNA-seq analysis
Data-sets for wild-type and T-bet deficient CD4+ T cells polarised in Th1 and Th2 conditions
were obtained from GEO (GSE38808). Raw reads were aligned to the mm10 build of the
murine genome using Subread [81], and subsequently mapped to RefSeq genes using feature-
Counts [82]. DESeq2 was used to normalise read counts by size factors, and call differentially
regulated genes using an empirical Bayes model and the Wald test followed by Benjamini-
Hochberg correction for multiple testing [83].
Motif analysis
The presence of T-bet motifs was assessed using FIMO [84] using previously compiled matri-
ces for T-bet binding obtained by ChIP-seq [54]. Sequences for T-bet binding sites were
obtained from the hg19 reference genome and SNPs were manually altered to the alternative
allele.
fGWAS
fGWAS analysis was performed as described in [56] using fGWAS version 0.3.3 with case con-
trol setting. Data were prepared for fGWAS using R and the GenomicRanges package to com-
pute overlap between binding sites and SNPs. Publicly available GWAS data were downloaded
from the websites of the relevant consortiums for UC, Crohn’s disease (http://www.
ibdgenetics.org/downloads.html), coronary artery disease (http://www.cardiogramplusc4d.
org/downloads/), and rheumatoid arthritis (http://plaza.umin.ac.jp/~yokada/datasource/
software.htm). Psoriasis data are from [85]. T-bet binding sites were identified as described
above. ENCODE ChIP-seq, FAIRE-seq and DNaseI hypersensitivity datasets were obtained
from the ENCODE website in bed format (http://ftp.ebi.ac.uk/pub/databases/ensembl/
encode/integration_data_jan2011). The complete ENCODE datasets combines DNaseI (125
annotations), FAIRE-seq (24 annotations), histone marks (117 annotations) and transcription
factor binding site datasets (S2 Table). In addition, we included GATA3 binding sites in Th1
and Th2 cells (GSE31320) [54], FOXP3 binding sites in Tregs [86], NF-κB binding sites in
lymphoblastoid cells [47] (GSE19486), and H3K27ac [58] and DHS [57] in Th1 and Th2 cells.
eQTL analysis
Celiac disease association was based on a case control association study of 12,041 celiac disease
cases and 12,228 controls [23]. Gene expression data were taken from [62]. eQTL analysis was
performed as described [63]. eQTL p-values were obtained by fitting a linear trend test regres-
sion between the expression of each gene and all variants 200 kb upstream and downstream
from each probe. Posterior computation was performed as described [63]. The regional associ-
ation plots for the eQTL and Biomarker datasets were created using LocusZoom [87] (http://
csg.sph.umich.edu/locuszoom/).
Colocalisation analysis was performed using the R package COLOC [63] based on single
variant summary statistics (log odds ratio, standard error for the log odds ratio for case control
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and effect size and standard error for effect size for eQTL study, in addition to MAF and physi-
cal position for each variant) and with the default settings provided with the R package.
Cell culture for oligonucleotide pull-down assays
Human CD4+ cells were isolated from buffy coats (UK National Blood Service, used under
REC reference number 10/H0804/65 from SE London Research Ethics Committee 2) using
RosetteSep human CD4+ T cell enrichment cocktail (STEMCELL Technologies) according to
manufacturer’s instructions and polarised towards a Th1 phenotype in supplemented RPMI as
described in above. Cells were harvested after a total of seven days of culture. YT cells were cul-
tured in RPMI medium (PAA) supplemented with 50 units/ml penicillin, 50 μg/ml streptomy-
cin (Gibco), 10 mM HEPES buffer solution (Fisher Scientific), 1 mM sodium pyruvate (Gibco),
1 × minimum essential medium-non essential amino acids (Gibco), 2 mM L-glutamine
(Gibco) and 10% foetal bovine serum (PAA). All cells were maintained at 37˚C in 5% CO2.
OligoFlow and pull-downs
Forward and reverse single-stranded oligos (Integrated DNA Technologies, S3 Table) for each
allele of each SNP were annealed by incubating at 94˚C for 5 mins, 65˚C for 10 mins, 25˚C for
10 mins and 4˚C thereafter in annealing buffer (50 mM Tris pH 8, 7 mM MgCl2 and 1 mM
DTT). For pull-down and western blot, 20μl of streptavidin agarose beads (Sigma) were used
per sample. For OligoFlow, 50 μl of Sphero streptavidin polystyrene particles (Spherotech
#SVP-100-4) were used per sample. Beads were washed twice in PBS and then once in anneal-
ing buffer. Beads were then incubated with double-stranded oligonucleotides for 1 hr at 4˚C,
washed twice in oligo buffer (10 mM Tris pH 8, 100 mM NaCl, 0.1 mM EDTA, 1 mM DTT,
5% glycerol, 1 mg/ml BSA Fraction V, 20 μg/ml dI/dC (Sigma, P4929) and Complete protease
inhibitor (Roche) and finally resuspended in 450 μl oligo buffer. Cells (30 million per sample)
were washed twice in PBS and lysed in 1 ml hypotonic buffer (20 mM HEPES pH 8, 10 mM
KCl, 1 mM MgCl2, 0.1% Triton X-100, 5% glycerol, 1 mM DTT and Complete protease inhibi-
tor) on ice for 5 mins. Lysed cells were pelleted and resuspended in 150 μl hypertonic buffer
(20 mM HEPES pH 8, 400 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 5% glycerol, 1 mM
DTT and Complete protease inhibitor). Debris was pelleted, 180 μl of supernatant containing
nuclear extract added to the beads and incubated on a rotor for 1 hour at 4˚C. For western
blotting, samples were then washed three times in oligo buffer and resuspended in SDS loading
buffer. For OligoFlow, 0.25 μg of anti-T-bet Alexa647 antibody (clone 4B10, BioLegend) was
added and samples incubated for a further 1 hr at 4˚C. Data (at least 30,000 events) were
acquired on a FACSCanto flow cytometer (BD Biosciences).
Western blotting
Oligonucleotide pull-down samples were heated in SDS loading buffer before transfer to nitro-
cellulose membrane. Samples were blocked in 5% milk in TBS-T (1 hr, RT) and incubated
with 1:1000 anti-T-bet (clone eBio4B10 (eBioscience); 4˚C overnight). Blots were washed
before addition of anti-mouse-HRP (GE Healthcare) and visualised with Enhanced Chemilu-
minescent Substrate (PerkinElmer) and exposed to film.
Supporting information
S1 Fig. T-bet binding at disease-associated SNPs. A. T-bet binding at further example T-bet
hit-SNPs. The number of sequencing reads from T-bet, IgG control and H3K27ac ChIP-
enriched DNA are plotted per million input-subtracted total reads and aligned with the human
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genome. DNaseI hypersensitivity data (2 replicates) are from ENCODE. B. The frequency dis-
tribution of posterior probabilities for association with IBD (from [21]) for SNPs [21] that do
not overlap (left) or that do overlap (right) a T-bet binding site. SNPs that overlap a T-bet bind-
ing site tend to have a higher posterior probability (binomial regression, p = 6.3x10-6).
(PDF)
S2 Fig. Confirmation of altered T-bet binding at rs1465321 by oligonucleotide pull-down.
A The effect of the different rs1465321 alleles on T-bet binding was assessed by oligonucleotide
pull-down followed by immunoblotting—a representative blot for rs1465321 is shown. B
Quantification of immunoblot band density, normalised to allele A. Error bars show standard
deviation (n = 4). The difference in T-bet binding to the G compared to A allele of rs1465321
was significant (p = 0.048, paired t-test).
(PDF)
S3 Fig. Heterozygous SNPs showing imbalanced T-bet binding. T-bet ChIP and input
sequencing reads that cross rs888096, rs1551399 and rs1551398 in two donors. In each case,
the number of reads that match the reference allele are shown in black and the alternative allele
in green.
(PDF)
S4 Fig. T-bet binding at the mouse Il18r1/Il18rap and Trib1 loci. The number of sequencing
reads from T-bet ChIP-enriched DNA from WT (GSM998272 and GSM836124) and T-bet
KO mouse Th1 cells (GSM998273) plotted per million input-subtracted total reads and aligned
with the mouse genome (mm9) at the Il18r1/Il18rap (A) and the Trib1 (B) loci.
(PDF)
S1 Table. Summary data for T-bet hit-SNPs.
(XLSX)
S2 Table. Functional annotation datasets used for fGWAS.
(XLS)
S3 Table. Oligonucleotide sequences used for OligoFlow.
(DOCX)
S4 Table. Heterozygous SNPs showing imbalanced T-bet binding in vivo.
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